Oncogenic Osteomalacia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

GARD: ¹⁹ Oncogenic osteomalacia is characterized by the development of a tumor that causes the bones to be weakened. This occurs when a tumor secretes a substance called fibroblast growth factor 23 (FGF23). FGF23 inhibits the ability of the kidneys to absorb phosphate. Phosphate is important for keeping bones strong and healthy. Therefore, this disease is characterized by a softening and weakening of the bones (osteomalacia). The disease also results in multiple biochemical abnormalities including high levels of phosphate in the urine (hyperphosphaturia) and low levels of phosphate in the blood (hypophosphatemia). The majority of tumors that cause Oncogenic osteomalacia are small and slow-growing. These tumors most commonly occur in the skin, muscles, or bones of the extremities or in the paranasal sinuses around the head. Most of these tumors are benign, meaning they are not associated with cancer. The exact reason that the tumors associated with Oncogenic osteomalacia develop is not known. The disease is diagnosed when a person experiences clinical features such as bone weakening and hyperphosphaturia and a tumor is found by imaging of the body.

MalaCards based summary: Oncogenic Osteomalacia, also known as oncogenic hypophosphatemic osteomalacia, is related to osteomalacia and hypophosphatemia. The drugs Pharmaceutical Solutions and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include bone, skin and bone marrow, and related phenotypes are hypophosphatemia and pathologic fracture

Orphanet: ⁵⁸ A rare paraneoplastic syndrome characterized by renal phosphate wasting and bone demineralization due to a phosphaturic mesenchymal tumor of the mixed connective tissue variant. It causes osteomalacia in adults with bone pain and pathological fractures, and rickets in children.

Wikipedia: ⁷⁵ Oncogenic osteomalacia, also known as oncogenic hypophosphatemic osteomalacia, is an uncommon disorder... more...

Sources

Related Diseases for Oncogenic Osteomalacia

Diseases related to Oncogenic Osteomalacia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 249)

#	Related Disease	Score
1	osteomalacia	11.1
2	hypophosphatemia	10.8
3	mesenchymal cell neoplasm	10.8
4	hemangiopericytoma, malignant	10.5
5	rickets	10.5
6	glass syndrome	10.5
7	charge syndrome	10.4
8	hyperparathyroidism	10.4
9	twin-reversed arterial perfusion sequence	10.4
10	hypophosphatemic rickets, x-linked recessive	10.3
11	hypophosphatemic rickets, x-linked dominant	10.3
12	adenoma	10.3
13	bone disease	10.3
14	spondyloarthropathy 1	10.2
15	osteogenic sarcoma	10.2
16	hemangioma	10.2
17	rare tumor	10.2
18	meningioma, familial	10.2
19	nephrocalcinosis	10.2
20	spondylitis	10.2
21	parathyroid adenoma	10.2
22	tn polyagglutination syndrome	10.2
23	global developmental delay, lung cysts, overgrowth, and wilms tumor	10.2
24	atypical teratoid rhabdoid tumor	10.2
25	paragangliomas 1	10.2
26	prostate cancer	10.2
27	fanconi syndrome	10.2
28	glomus tumor	10.2
29	fibrous histiocytoma	10.2
30	cutaneous fibrous histiocytoma	10.2
31	malignant peripheral nerve sheath tumor	10.2
32	nijmegen breakage syndrome	10.1
33	tenosynovial giant cell tumor	10.1
34	schimmelpenning-feuerstein-mims syndrome	10.1
35	neuroendocrine tumor	10.1
36	aminoaciduria	10.1
37	thyroid carcinoma	10.1
38	hypophosphatemic rickets, autosomal dominant	10.1
39	short stature, onychodysplasia, facial dysmorphism, and hypotrichosis	10.1
40	small cell carcinoma	10.1
41	fibroma	10.1
42	neurilemmoma	10.1
43	inappropriate adh syndrome	10.1
44	angiolipoma	10.1
45	myopathy	10.1
46	neurofibromatosis	10.1
47	syndrome of inappropriate antidiuretic hormone	10.1
48	paraneoplastic syndromes	10.1
49	chondromyxoid fibroma	10.1
50	gastric antral vascular ectasia	10.0

Graphical network of the top 20 diseases related to Oncogenic Osteomalacia:

Sources

Symptoms & Phenotypes for Oncogenic Osteomalacia

Human phenotypes related to Oncogenic Osteomalacia:

⁵⁸ ³⁰ (show all 27)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	hypophosphatemia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002148
2	pathologic fracture ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002756
3	hyperphosphaturia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0003109
4	renal phosphate wasting ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000117
5	elevated circulating alkaline phosphatase concentration ³⁰	Hallmark (90%)		HP:0003155
6	bone pain ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002653
7	proximal muscle weakness ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003701
8	gait disturbance ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001288
9	abnormality of femur morphology ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002823
10	osteosarcoma ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002669
11	hypocalcemia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002901
12	tibial bowing ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002982
13	abnormality of fibula morphology ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002991
14	fibrous dysplasia of the bones ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0010734
15	abnormality of the tarsal bones ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001850
16	neoplasm of head and neck ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012288
17	abnormal pelvis bone morphology ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0040163
18	giant cell tumor of bone ³⁰	Occasional (7.5%)		HP:0011847
19	abnormal vertebral morphology ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0003468
20	neurofibromas ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001067
21	carcinoma ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0030731
22	muscle weakness ⁵⁸		Very frequent (99-80%)
23	abnormality of the foot ⁵⁸		Occasional (29-5%)
24	increased susceptibility to fractures ⁵⁸		Frequent (79-30%)
25	giant cell tumor of bone ⁵⁸		Occasional (29-5%)
26	neoplasm of the skeletal system ⁵⁸		Frequent (79-30%)
27	elevated alkaline phosphatase ⁵⁸		Very frequent (99-80%)

Sources

Drugs & Therapeutics for Oncogenic Osteomalacia

Drugs for Oncogenic Osteomalacia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Pharmaceutical Solutions

Phase 4

2

Immunoglobulins

Phase 4

3

Antibodies

Phase 4

4

Infigratinib

Approved, Investigational

Phase 2

872511-34-7

53235510

5

Mitogens

Phase 2

6

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid

Phase 1

7

Chelating Agents

Phase 1

8

Somatostatin

Approved, Investigational

Early Phase 1

38916-34-6, 51110-01-1

53481605 16129706

9

Dimenhydrinate

Approved

523-87-5

10660

10

D-Phenylalanine

Approved, Experimental, Investigational, Nutraceutical

Early Phase 1

63-91-2, 673-06-3

6140 71567

11

Fluorodeoxyglucose F18

Interventional clinical trials:

(show all 12)

#	Name	Status	NCT ID	Phase	Drugs
1	An Open-Label, Multi Center, Single-Cohort, Post-Marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Adult Chinese Patients With Tumor-Induced Osteomalacia (TIO)	Recruiting	NCT05357573	Phase 4	KRN23
2	A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)-Associated Osteomalacia	Completed	NCT02304367	Phase 2
3	A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Patients With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome and a Post-marketing Study of KRN23 Switched From the Phase 2 Trial	Completed	NCT02722798	Phase 2	KRN23
4	68Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia	Recruiting	NCT03736564	Phase 1, Phase 2
5	BGJ398 for the Treatment of Tumor-Induced Osteomalacia	Terminated	NCT03510455	Phase 2	BGJ398
6	Head-to-head Comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in Patients With Tumor-induced Osteomalacia	Unknown status	NCT04689893	Phase 1	68Ga-Dotatate;68Ga-DOTA-JR11
7	Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors	Unknown status	NCT02331966
8	68Ga-DOTATATE PET/CT for Detection and Evaluation of the Causative Tumor of Oncogenic Osteomalacia	Unknown status	NCT01524016	Early Phase 1	68Ga-DOTATATE
9	Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia	Unknown status	NCT01660308
10	Tumor-induced Osteomalacia Disease Monitoring Program (TIO DMP)	Recruiting	NCT04783428
11	Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced Osteomalacia	Recruiting	NCT04045834
12	Expanded Access to Burosumab	Available	NCT03775187

Search NIH Clinical Center for Oncogenic Osteomalacia

Sources

Genetic Tests for Oncogenic Osteomalacia

Sources

Anatomical Context for Oncogenic Osteomalacia

Organs/tissues related to Oncogenic Osteomalacia:

MalaCards : Bone, Skin, Bone Marrow, Prostate, Breast, Lymph Node, Kidney

Sources

Publications for Oncogenic Osteomalacia

Articles related to Oncogenic Osteomalacia:

(show top 50) (show all 752)

#	Title	Authors	PMID	Year
1	The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome. ⁶²	Sugarman J...Carpenter TO	36341949	2023
2	Tumour-induced osteomalacia: a rare cause of chronic pain and weakness. ⁶²	Nasr JT...Taskin M	35896375	2022
3	Reply to: appropriate dosing of burosumab in tumor-induced osteomalacia. ⁶²	Crotti C...Varenna M	36454247	2022
4	Appropriate dosing of burosumab in tumor-induced osteomalacia. ⁶²	Colangelo L...Minisola S	36454246	2022
5	Tumour-induced osteomalacia due to residual benign glomangioma. ⁶²	Barai R...Cespedes L	36357106	2022
6	Hyperparathyroidism in a Large Cohort of Chinese Patients with Tumor-Induced Osteomalacia. ⁶²	Ni X...Xia W	36334263	2022
7	Tumor-induced osteomalacia. ⁶²	Annamalai AK...Srinivasan KG	36272746	2022
8	Tumor-induced osteomalacia combined with acromegaly: A case report. ⁶²	Li X...Xia W	36056464	2022
9	TUMOR-INDUCED OSTEOMALACIA: A COMPREHENSIVE REVIEW. ⁶²	Minisola S...Thakker RV	36327295	2022
10	Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia. ⁶²	Hartley IR...Florenzano P	36093861	2022
11	New treatments for rare bone diseases: hypophosphatemic rickets/osteomalacia. ⁶²	Marques JVO...Borba VZC	36382755	2022
12	Rickets guidance: part II-management. ⁶²	Haffner D...Schnabel D	35352187	2022
13	Novel Therapeutic Agents for Rare Diseases of Calcium and Phosphate Metabolism. ⁶²	Roumpou A...Kassi E	36049757	2022
14	Proceedings of the 2022 Santa Fe Bone Symposium: Current Concepts in the Care of Patients with Osteoporosis and Metabolic Bone Diseases. ⁶²	Lewiecki EM...Tosi LL	36280582	2022
15	Phosphatonins: From Discovery to Therapeutics. ⁶²	Kritmetapak K...Kumar R	36210014	2022
16	Intracranial phosphaturic mesenchymal tumors. A case report and review of literature. ⁶²	Kojima D...Hirose Y	35880350	2022
17	Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases. ⁶²	Bosman A...Zillikens MC	35857061	2022
18	The Nose that Broke the Hip! Tumor Induced Osteomalacia Secondary to Phosphaturic Mesenchymal Nasal Tumor : A Case Report. ⁶²	Rangaswamy D...Venkataramani N	36452858	2022
19	Hemiarthroplasty for tumor-induced osteomalacia caused by tumor localized in femoral head: a case report. ⁶²	Arita S...Yamazaki M	36285172	2022
20	Tumor-induced osteomalacia. ⁶²	Aoyama N...Terada Y	36066446	2022
21	[Tumor-induced osteomalacia caused by an orbital tumor: a case report]. ⁶²	Jing DL...Wang W	36069094	2022
22	High prevalence of vertebral deformity in tumor-induced osteomalacia associated with impaired bone microstructure. ⁶²	Ni X...Xia W	36097315	2022
23	Phosphaturic Mesenchymal Tumors in the Head and Neck Demonstrate a Broad Clinical and Morphologic Spectrum. ⁶²	Hulme KR...Gupta R	35119617	2022
24	Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1). ⁶²	Bai X...Karaplis AC	35896139	2022
25	Advances in understanding of phosphate homeostasis and related disorders. ⁶²	Michigami T	35831119	2022
26	Ovarian Teratoma Causing Oncogenic Osteomalacia: An Instance of Serendipity. ⁶²	Paul J...Cherian KE	35923504	2022
27	Clinical Challenges in Diagnosis, Tumor Localization and Treatment of Tumor-Induced Osteomalacia: Outcome of a Retrospective Surveillance. ⁶²	Hidaka N...Ito N	35690913	2022
28	Long-term use of burosumab for the treatment of tumor-induced osteomalacia. ⁶²	Crotti C...Varenna M	35925260	2022
29	Identification of Small-Molecule Inhibitors of Fibroblast Growth Factor 23 Signaling via In Silico Hot Spot Prediction and Molecular Docking to α-Klotho. ⁶²	Liu SH...Petridis L	35868851	2022
30	Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor-Induced Osteomalacia. ⁶²	Hartley IR...Gafni RI	35991529	2022
31	Tumor-induced Osteomalacia: A Systematic Review and Individual Patient's Data Analysis. ⁶²	Rendina D...Strazzullo P	35468192	2022
32	Tumor-induced osteomalacia characterized by "painful knee joint with difficulty in moving": a case report. ⁶²	Jiang L...Xu Y	35804355	2022
33	[FGF23 tumor induced osteomalacia]. ⁶²	Gronskaia SA...Melnichenko GA	36337019	2022
34	Phosphaturic Mesenchymal Tumor: An Unusual Cause of Stress Fractures Presenting to Sports Medicine. ⁶²	Solaiman RH...Ogilvie CM	35974843	2022
35	Phosphaturic Mesenchymal Tumor. ⁶²	Benson JC...DeLone DR	35589138	2022
36	Tumor induced osteomalacia - A long way toward correct diagnosis and management. ⁶²	Filipova L...Lazurova I	35281212	2022
37	Hypophosphatemia related to a neuro-endocrine tumor of the pancreas: A case report. ⁶²	Pickering ME...Oris C	35337828	2022
38	Persistence and recurrence in tumor-induced osteomalacia: A systematic review of the literature and results from a national survey/case series. ⁶²	Cianferotti L...Brandi ML	35381903	2022
39	The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations. ⁶²	Heijboer AC...Cavalier E	35665817	2022
40	A Case Report of Hypophosphatemia Leading to the Diagnosis of Mesothelioma. ⁶²	Goh ZW...Hasan F	35755540	2022
41	Diagnostic Utility of Somatostatin Receptor 2A Immunohistochemistry for Tumor-induced Osteomalacia. ⁶²	Lee S...Rhee Y	35184184	2022
42	Challenging case of tumour-induced osteomalacia. ⁶²	Kumar P...Jain N	35589273	2022
43	Serum Metabolomics Reveals Dysregulation and Diagnostic Potential of Oxylipins in Tumor-induced Osteomalacia. ⁶²	Gong Y...Xia W	34904633	2022
44	FGF-23 transmitted tumor - induced hypophosphatemic osteomalacia: A rare case of a young woman with recurrent fractures and review of the literature. ⁶²	Frank FA...Krieg AH	35169537	2022
45	[Tumor localization and treatment of tumor-induced osteomalacia]. ⁶²	Beil FT...Oheim R	35103802	2022
46	Bone Impairment in a Large Cohort of Chinese Patients With Tumor-Induced Osteomalacia Assessed by HR-pQCT and TBS. ⁶²	Ni X...Xia W	34796540	2022
47	Phosphaturic Mesenchymal Tumor in the Maxillofacial Region: A Diagnostic Dilemma. ⁶²	Bhat A...Kumar K	35400904	2022
48	Tumor - Induced Osteomalacia Associated with a Maxillary Tumor in Children: A Case Report and Review of the Literature. ⁶²	Thi HN...Vilaiyuk S	35135186	2022
49	Pindborg Tumor-An Uncommon Odontogenic Tumor Detected by 68Ga-DOTATOC. ⁶²	Herden A...Furth C	35204480	2022
50	False positive 68Ga-DOTATATE PET-CT in Hereditary hypophosphatemic-osteomalacia mimicking culprit lesions of tumor induced osteomalacia. ⁶²	Parghane RV...Basu S	35197273	2022

Sources

Genes for Oncogenic Osteomalacia

Sources

Variations for Oncogenic Osteomalacia

Sources

Expression for Oncogenic Osteomalacia

Search GEO for disease gene expression data for Oncogenic Osteomalacia.

Sources

Pathways for Oncogenic Osteomalacia

Sources

GO Terms for Oncogenic Osteomalacia

Sources

Sources for Oncogenic Osteomalacia

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

TIO MCID: ONC003 MIFTS: 37	Oncogenic Osteomalacia (TIO) Categories: Bone diseases, Endocrine diseases, Nephrological diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Oncogenic Osteomalacia (TIO)

Aliases & Classifications for Oncogenic Osteomalacia

MalaCards integrated aliases for Oncogenic Osteomalacia:

Characteristics:

Age Of Onset:

Classifications:

External Ids:

Summaries for Oncogenic Osteomalacia

Related Diseases for Oncogenic Osteomalacia

Diseases related to Oncogenic Osteomalacia via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Oncogenic Osteomalacia:

Symptoms & Phenotypes for Oncogenic Osteomalacia

Human phenotypes related to Oncogenic Osteomalacia:

Drugs & Therapeutics for Oncogenic Osteomalacia

Drugs for Oncogenic Osteomalacia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Genetic Tests for Oncogenic Osteomalacia

Anatomical Context for Oncogenic Osteomalacia

Organs/tissues related to Oncogenic Osteomalacia:

Publications for Oncogenic Osteomalacia

Articles related to Oncogenic Osteomalacia:

Genes for Oncogenic Osteomalacia

Variations for Oncogenic Osteomalacia

Expression for Oncogenic Osteomalacia

Pathways for Oncogenic Osteomalacia

GO Terms for Oncogenic Osteomalacia

Sources for Oncogenic Osteomalacia